AstraZeneca: drug approval in Japan
AstraZeneca’s Imfinzi has been approved in Japan for the treatment of patients with extensive-stage small cell lung cancer, in combination with etoposide plus a choice of platinum chemotherapy.
From a chartist point of view, the stock consolidates above a key support at 8310. As long as this level is not broken, a bounce would be expected towards 9113 at first.
From a chartist point of view, the stock consolidates above a key support at 8310. As long as this level is not broken, a bounce would be expected towards 9113 at first.
Source : TradingVIEW, Gain Capital
Latest market news
Yesterday 01:26 PM
Yesterday 01:00 PM
Yesterday 10:30 AM
March 27, 2024 11:52 PM
March 27, 2024 01:41 PM
March 27, 2024 01:14 PM